Rob Jones currently serves as the Vice President of Global Bioservices at Cryoport, where he is at the forefront of a transformative initiative aimed at enhancing the supply chain for cell and gene therapies. With a robust background as a Commercial Director in the life...
Rob Jones currently serves as the Vice President of Global Bioservices at Cryoport, where he is at the forefront of a transformative initiative aimed at enhancing the supply chain for cell and gene therapies. With a robust background as a Commercial Director in the life sciences and advanced therapy sectors, Rob brings a wealth of expertise in Good Manufacturing Practice (GMP), cryogenic supply chain management, and clinical trials. His unique qualifications in Haematology and Blood Transfusion Medicine, gained from his early career at the UK Blood Transfusion Service, provide him with a solid foundation in the complexities of biological materials and their critical role in therapeutic applications.
In his current role, Rob is leading the establishment of a new business division that will expand Cryoport's portfolio of services to better support the burgeoning cell and gene therapy market. This expansion is not only focused on enhancing GMP services but also aims to broaden geographic coverage, ensuring that innovative therapies can reach patients in a timely and efficient manner. Rob's strategic vision is pivotal in navigating the dynamic landscape of the Advanced Therapy industry, which is continuously evolving with new technologies and regulatory challenges.
His extensive skill set includes biotechnology, molecular biology, and technology transfer, which are essential for driving successful clinical research and ensuring compliance with FDA regulations. By leveraging his knowledge in biochemistry and microbiology, Rob is positioned to implement best practices in supply chain validation, ultimately contributing to the successful delivery of life-saving therapies. As he spearheads this initiative, Rob Jones is not only shaping the future of Cryoport but also making a significant impact on the global healthcare landscape.
